Compare CVS Health Corp (CVS) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B). The key difference: CVS Health Corp is far larger — about 15.3× Direxion Daily S&P 500 Bull 3X Shares's market cap, and CVS Health Corp pays a 3.03% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| CVS | SPXL | |
|---|---|---|
Market Cap | $112.29B | $7.36B |
Volume | 7,763,676 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $110.60 | $301.38 |
52-Week Low | $70.08 | $170.20 |
Typical Hold Time | 83 Days | 32 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07B in 2025, though net income margin compressed to 1.18%. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
CVS presents a mixed outlook with solid revenue growth and analyst bullishness (85% buy ratings, $111.20 consensus target) offset by profitability pressures and a bearish technical trend. Key risks include reimbursement pressure and ongoing legal investigations, but the stock offers value with a low P/S of 0.27 and dividend yield support.
SPXL trades at $297.97, up 0.38% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 66.91 suggesting mild overbought conditions. Support levels begin at $289 with resistance at $297. Recent news highlights S&P 500 valuation debates and profit growth expectations shifting from 35% in 2026 to 15% in 2027.
Outlook remains cautiously optimistic given the ETF's leveraged exposure to S&P 500 momentum. Key risks include market concentration in top holdings and potential profit growth deceleration. The technical setup favors continued upside if $297 resistance breaks, while failure to hold $289 support could signal near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
